A potent neuromedin U receptor 2-selective alkylated peptide

https://doi.org/10.1016/j.bmcl.2017.09.019Get rights and content

Abstract

Neuromedin U (NMU) mediates various physiological functions via NMUR1 and NMUR2 receptors. NMUR2 has been considered a promising treatment option for diabetes and obesity. Although NMU-8, a shorter peptide, has potent agonist activity for both receptors, it is metabolically unstable. Therefore, NMU-8 analogs modified with long-chain alkyl moieties via a linker were synthesized. An octadecanoyl analog (17) with amino acid substitutions [αMePhe19, Nle21, and Arg(Me)24] and a linker [Tra-γGlu-PEG(2)] dramatically increased NMUR2 selectivity, with retention of high agonist activity. Subcutaneous administration of 17 induced anorectic activity in C57BL/6J mice. Owing to its high metabolic stability, 17 would be useful in clarifying the physiological role and therapeutic application of NMU.

Section snippets

Acknowledgments

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. We would like to thank Editage (www.editage.jp) for English language editing.

References (45)

  • N. Minamino et al.

    Biochem Biophys Res Commun

    (1985)
  • F. O'Harte et al.

    Peptides

    (1991)
  • R. Fujii et al.

    J Biol Chem

    (2000)
  • M. Kojima et al.

    Biochem Biophys Res Commun

    (2000)
  • R. Raddatz et al.

    J Biol Chem

    (2000)
  • P.G. Szekeres et al.

    J Biol Chem

    (2000)
  • M. Hosoya et al.

    J Biol Chem

    (2000)
  • L. Shan et al.

    J Biol Chem

    (2000)
  • Y. Masuda et al.

    Peptides

    (2017)
  • N.V. Katre

    Adv Drug Deliv Rev

    (1993)
  • F.M. Veronese

    Biomaterials

    (2001)
  • P. Ingallinella et al.

    Bioorg Med Chem

    (2012)
  • H. Inooka et al.

    Bioorg Med Chem

    (2017)
  • C.C. Appeldoorn et al.

    J Biol Chem

    (2003)
  • T. Asami et al.

    Bioorg Med Chem Lett

    (2012)
  • IUPAC-IUB Commission on Biochemical Nomenclature

    Symbols for amino-acid derivatives and peptides. Recommendations (1971)

    J Biol Chem

    (1972)
  • Obesity and Overweight. World Health Organization; 2016....
  • P.J. Brighton et al.

    Pharmacol Rev

    (2004)
  • K. Mori et al.

    EMBO J

    (2005)
  • J.D. Mitchell et al.

    Br J Pharmacol

    (2009)
  • J.A. Hedrick et al.

    Mol Pharmacol

    (2000)
  • A.D. Howard et al.

    Nature

    (2000)

    • Cited by (6)

    • Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives

      2018, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      Two alkylated glucagon-like peptide-1 (GLP-1) analogs, liraglutide26–28 and semaglutide29, exhibited potent anti-diabetic effect and induced significant body weight loss in clinical studies for once-daily and once-weekly formulations, respectively. Four derivatives of 1 with eicosanedioic acid (Eda) with the alkyl moiety at the Lys30 side chain were synthesized using a tranexamic acid (Tra)-γGlu-PEG(2) linker, which was effective for NMUR2 selective alkylated peptides,30 with the expectation that they would retain Y2R binding affinity (Table 3, Fig. 1, Fig. S1). Compound 7 [Iva25, γMeLeu28] showed high Y2R binding affinity and moderate anorectic activity in lean mice.

    • Unanticipated Characteristics of a Selective, Potent Neuromedin-U Receptor 2 Agonist

      2022, ACS Bio and Med Chem Au

    • Peptide Tool-Driven Functional Elucidation of Biomolecules Related to Endocrine System and Metabolism

      2022, Chemical and Pharmaceutical Bulletin

    • The chemistry and biology of guanidine secondary metabolites

      2021, Natural Product Reports

    • Neuromedin U and structural analogs: An overview of their structure, function and selectivity

      2020, Current Medicinal Chemistry

    • Synthesis and in Vitro Evaluation of Stabilized and Selective Neuromedin U-1 Receptor Agonists

      2018, ACS Medicinal Chemistry Letters
    View full text
    © 2017 Elsevier Ltd. All rights reserved.